“New Era for Transplants”: Roswell Park Reports Increased Survival Outcomes One Year Following Allogeneic Transplant
-
July 8, 2026
Clinical Report: Roswell Park Reports Increased Survival Outcomes One Year Following Allogeneic Transplant
Overview
Roswell Park Comprehensive Cancer Center has achieved a 92.6% one-year survival rate following allogeneic hematopoietic cell transplantation (alloCT), significantly higher than the national average of approximately 80%.
Background
Allogeneic hematopoietic cell transplantation is a critical treatment option for various blood cancers and noncancerous conditions. Recent advancements in transplant protocols and patient management have the potential to enhance survival rates.
Data Highlights
The one-year survival rate at Roswell Park is 92.6%, compared to the national rate of approximately 80%.
Key Findings
- 92.6% one-year survival rate for patients receiving alloCT at Roswell Park in 2024.
- Operational changes included reduced IV fluid and antibiotic use, increased exercise, and nutrition focus.
- Transplantation now considered for liquid tumor patients up to age 85.
- Cost reductions achieved, with drug costs halved compared to previous protocols.
- Patients may return home as early as 28 days post-transplant if healthy enough.
Clinical Implications
The findings suggest that implementing evidence-based operational changes can significantly improve patient outcomes in allogeneic transplantation. Healthcare providers should consider these strategies to enhance care and accessibility for a broader patient population.
Conclusion
The advancements reported by Roswell Park mark a significant step forward in the field of hematopoietic cell transplantation, with the potential to improve survival rates and patient care.
Related Resources & Content
- Roswell Park Comprehensive Cancer Center, Roswell Park’s Stem Cell Transplant Program Recognized by Optum as Center of Excellence, 2024 -- https://physicianresources.roswellpark.org/news/roswell-park-s-stem-cell-transplant-program-recognized-by-optum-as-center-of-excellence
- Roswell Park Comprehensive Cancer Center, Immune Checkpoint Inhibitors ‘High-Risk Yet Promising’ for Cancer Patients Who Undergo Organ Transplant, 2024 -- https://physicianresources.roswellpark.org/news/immune-checkpoint-inhibitors-high-risk-yet-promising-for-cancer-patients-who-undergo-organ-transplant
- Bone Marrow Transplantation, The 50th Annual Conference of the European Society for Blood and Marrow Transplantation: Physician Presentations (O009-O154), 2024 -- https://www.nature.com/articles/s41409-024-02347-7
- JAMA Network Open, Evolving Opportunities and Persisting Disparities in Allogeneic Transplant, 2024 -- https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2848616
- NCCN Clinical Practice Guidelines In Oncology - Hematopoietic Cell Transplantation, Version 3.2025
- NIH Chronic Graft-Versus-Host Disease Consensus Conference 2025 Update
- 2025 EBMT Practice Recommendations
- CIBMTR Center-Specific Survival Report Methodology
- Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin | New England Journal of Medicine
- Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation | Journal of Clinical Oncology
- A prospective clinical trial of GVHD prophylaxis with posttransplant cyclophosphamide and abatacept - PubMed
- Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL) - PMC
- Antifungal prescription and stewardship in hematology and hematopoietic stem cell transplantation units worldwide: an international survey of EHA-SWG Infections in Hematology | Bone Marrow Transplantation
- Antimicrobial Stewardship & Healthcare Epidemiology (2025), 5, e265, 1–8
Based on findings from:
“New Era for Transplants”: Roswell Park Reports Increased Survival Outcomes One Year Following Allogeneic Transplant
Roswell Park Comprehensive Cancer Center, 2026.
https://physicianresources.roswellpark.org/videos/new-era-for-transplants-roswell-park-reports-increased-survival-outcomes-one-year-following-allogeneic-transplant
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
